Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: gout

New Study Raises Cardiovascular Questions about Febuxostat for Gout

  |  

New research raises questions about the cardiovascular safety of febuxostat for gout patients compared with allopurinol. The study found that although febuxostat was noninferior to allopurinol, febuxostat-treated patients had similar overall rates of major adverse cardiovascular events as allopurinol-treated patients, but had higher rates of all-cause mortality and cardiovascular mortality…

Study Finds Newer Gout Drug Poses Risk to Heart Patients

Gene Emery  |  

(Reuters Health)—Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded. The risk of death from cardiovascular disease was 34% higher with febuxostat than with allopurinol. When researchers considered deaths from any cause, the risk was 22% higher…

Patients with Gout May Be More Likely to Develop Osteoporosis

Scott Baltic  |  

NEW YORK (Reuters Health)—People with gout face a modestly increased risk, of about 20%, for developing osteoporosis, compared to people without gout, researchers in Taiwan suggest. In their population-based study to examine a possible association between gout and subsequent osteoporosis, Dr. Victor C. Kok of Asia University (Taiwan), Taichung, and colleagues retrospectively analyzed data from…

Hyperuricemia Doesn’t Always Indicate Gout in Rheumatic Disease

Veronika Sharp, MD, Alice Chuang, MD, Lily Kao, MD, RMSK, & Midori Jane Nishio, MD, RhMSUS  |  

A 57-year-old Ghanaian woman was referred to our rheumatology practice with acute, left elbow swelling and pain. The referring oncologist suspected gout, because the patient had hyperuricemia. Six months before, the patient was diagnosed with stage IV human T-lymphotropic virus type 1 (HTLV-1)-associated adult T cell lymphoma (ATLL). Her initial oncologic manifestations included multiple thoracic,…

FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout

Reuters Staff  |  

(Reuters)—Ironwood Pharmaceuticals Inc. said on Monday the U.S. Food and Drug Administration (FDA) approved its oral drug to treat a condition associated with gout. The company’s once-daily drug, Duzallo (lesinurad and allopurinol), was approved to treat hyperuricemia in patients with gout, Ironwood said. Duzallo combines the standard-of-care treatment, allopurinol, with Ironwood’s lesinurad to treat inefficient…

Rheumatology Coding Corner Question: Established Patient Office Visit with Acute Gout

  |  

A 66-year-old female patient returns to the office complaining of swelling and a burning pain in her right first toe. She rates the pain level at a 9 out of 10. She currently takes an over-the-counter non-steroidal anti-inflammatory drug (NSAID), but it has done little to alleviate the pain. This is her second episode this…

Rheumatology Coding Corner Answer: Established Patient Office Visit with Acute Gout

  |  

Take the challenge. CPT: 99214-25, 89060, 20600-RT ICD-10: M10.271, T50.2X5A, I10 This is an established outpatient visit. This encounter is coded as 99213, because it included: History—Detailed: The history of present illness is extended, the review of systems is extended, and the past medical and social histories are documented. Examination—Detailed: Seven organ systems are examined….